Final Decision: BUY

Reason: Sun Pharma's Q2 results have exceeded expectations with a 28% jump in net profit, beating analyst estimates, and the company has also entered into an exclusive agreement for commercializing anti-cancer immunotherapy, indicating strong growth potential. Additionally, analysts have provided a positive target price, suggesting a BUY call.